Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00512798
Status:
TERMINATED
Last Update Posted:
2012-10-02
First Post:
2007-08-06
Brief Title:
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Vanderbilt-Ingram Cancer Center
Organization Data
Organization:
Vanderbilt-Ingram Cancer Center
Class:
OTHER
Study ID:
VICC PHI 0241
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
Jeffrey A Sosman MD
Responsible Party Title:
Professor of Medicine Director Melanoma and Tumor Immunotherapy Program Medical Oncologist
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Vanderbilt-Ingram Cancer Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |